Maggie Cheang: Intrinsic subtypes with survival outcomes on CDK4/6 inhibitors
Maggie Cheang, Team Leader of Genomic Analysis – Clinical Trials at The Institute of Cancer Research, shared on X:
“Our paper on intrinsic subtypes with survival outcomes on CDK4/6 inhibitors is finally out! In collaboration with Pfizer Inc. we used patient samples from two CDK4/6 inhibitor trials, PALLET and PALOMA-2
Authors: Maggie Chon U. Cheang, Mothaffar Rimawi, Stephen Johnston, Samuel A. Jacobs, Judith Bliss, Katherine Pogue-Geile, Lucy Kilburn, Zhou Zhu, Eugene F. Schuster, Hui Xiao, Lisa Swaim, Shibing Deng, Dongrui R. Lu, Eric Gauthier, Jennifer Tursi, Dennis J. Slamon, Hope S. Rugo, Richard S. Finn, Yuan Liu.
Presenting the first head-to-head comparison of intrinsic breast cancer subtyping methodologies. We found crucial discrepancies in survival outcomes linked to these methods. Using standardized and validated computation methods is vital
Our study revealed significant disagreement (less than 70% agreement) in classifying ER+/HER2- tumors between the PAM50 (Prosigna, the widely accepted gold standard) and the open-source AIMS method (a surrogate for PAM50).
This highlights the importance of accurate subtyping to prevent misguided treatment decisions. Consistent with prior studies, the predictive value of palbociclib treatment was confirmed, with PAM50/Prosigna subtyping prevailing.”
Source: Maggie Cheang/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023